Dialog window

Delsie Braganza

Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to help clients understand the Canadian and US requirements, set targets to achieve compliance, and attain their goals to get products to market.

Delsie is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all regulatory compliance reviews and submissions made to Health Canada and the US FDA.

Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS).

When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

Dialog window

Jennifer Porter, BA Psychology, MBA – President & CEO

​Having started at Focal Point Research in 2011, Jenn has been fully engaged in the company and since day one, has leveraged her MBA and interest in the regulated products industries to grow her passion for the business and services offered. 

Jenn has excelled at building on initial conversations with a variety of companies from all industries seeking regulatory and quality assurance services. She has developed strong relationships with each client, offering each one a unique opportunity to have the Focal Point Research team help them develop successful strategies and bring products to market, while ensuring their compliance needs are being fulfilled. 

Jenn has not only been a leader internally, but a key contact for all clients and in 2021, Jenn was the obvious choice to lead Focal Point Research into the future as the successor to company founder, Rob Fichtner.

Jennifer balances her career by honouring her wanderlust, spending her leisure time golfing, and enjoying the outdoors with her loving dog.

(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
      • Natural Health Products
      • Topical OTC Drugs
      • Medical Devices
      • Consumer Products
      • FDA Consulting
      • Veterinary Health Product
    • Health Canada Consultants
      • Regulatory Affairs
      • Pharmacovigilance Services
      • MoCRA
      • Ingredient Compliance
      • CEPA
      • Good Manufacturing Practices (GMP) Training
      • Technology
  • Innovation
  • Articles
  • Contact
Select Page
Minister of the Environment Amends DSL to Apply “P” Designation to Over 200 Polymers

Minister of the Environment Amends DSL to Apply “P” Designation to Over 200 Polymers

by Sagarika Sharma | Nov 6, 2026 | Health Canada Updates, Importation of NHPs, Our View

Following up on developments initially highlighted earlier this year, regulatory authorities have officially finalized updates to the Domestic Substances List (DSL) concerning specific polymer classifications.  Previously, a formal notice of intent was issued in...
Health Canada Updates DEL Screening Process to Improve Efficiency

Health Canada Updates DEL Screening Process to Improve Efficiency

by Sagarika Sharma | Nov 6, 2026 | Health Canada Updates, OTC Drugs

Health Canada has published Drug Establishment Licensing (DEL) Bulletin No. 196, officially dated October 15, 2026. This bulletin introduces procedural modifications to how Health Canada screens DEL applications, aiming to minimize red tape and enhance overall...
Health Canada Updates Interim Compliance Approach for NHP Labelling Updates

Health Canada Updates Interim Compliance Approach for NHP Labelling Updates

by Sagarika Sharma | Nov 6, 2026 | Health Canada Updates, Importation of NHPs, Our View

Health Canada has published a new bulletin addressing updates to its interim compliance approach for labelling-related monographs. The full bulletin, officially titled “Interim Compliance Approach to Labelling-Related Monograph Updates,” is now available...
Health Canada to discontinue public posting of initial inspection deficiencies

Health Canada to discontinue public posting of initial inspection deficiencies

by Srishti Chaudhari | Nov 6, 2026 | Health Canada Updates, Our View

Effective October 21, 2026, HC is discontinuing the public posting of Initial Inspection Deficiencies (IIDs) in the Drug and Health Products Inspections Database (DHPID) for drug Good Manufacturing Practices (GMP), Natural Health Products (NHP) GMP and Good...
Health Canada to discontinue public posting of initial inspection deficiencies

Streamlining Post-Market Vigilance: Health Canada Overhauls Guidance on Notifying Foreign Regulatory Actions

by Sagarika Sharma | Oct 13, 2026 | Health Canada Updates

Health Canada has announced a modernized regulatory framework governing how Market Authorization Holders (MAHs) report safety actions and restrictions occurring in international jurisdictions. Officially taking effect on October 1, 2026, the revised guidance...
Health Canada Updates Summary Reporting Guidance for Marketed Drugs and Natural Health Products

Health Canada Updates Summary Reporting Guidance for Marketed Drugs and Natural Health Products

by Sagarika Sharma | Oct 13, 2026 | Health Canada Updates, Importation of NHPs, Natural Health Products

Health Canada has announced an updated version of its foundational guidance, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products – Guidance Document for Industry, officially entering into force on October 1, 2026. Replacing...
« Older Entries

Recent Posts

  • Cosmetic or Therapeutic? – The regulatory grey zone
  • FDA Finalizes Guidance on Mandatory Cosmetic Recalls Under MoCRA
  • Heightened Scrutiny on 1,4-Dioxane Limits in Consumer Goods
  • Upcoming California DTSC Deadlines for Nail Products Containing TPhP
  • Escalating State-Level PFAS Reporting Mandates for 2026–2027

Recent Comments

    Archives

    • November 2026
    • October 2026
    • September 2026
    • August 2026
    • June 2026
    • April 2026
    • February 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • June 2025
    • May 2025
    • March 2025
    • October 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • December 2023
    • November 2023
    • September 2023
    • August 2023
    • July 2023
    • June 2023
    • January 2023
    • December 2022
    • November 2022
    • July 2022
    • June 2022
    • April 2022
    • March 2022
    • October 2021
    • July 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • California Cosmetic Regulations
    • California Office of Environmental Health Hazard Assessment
    • California SB 54
    • Canadian Environmental Protection Act
    • Canadian Quality Assurance
    • Canadian Regulatory
    • CARB
    • Cosmetic Ingredient Hotlist
    • Cosmetics
    • Cosmetics
    • Environment and Climate Change Canada
    • European Regulatory
    • Events/Company Updates
    • FDA
    • Federal Plastics Registry
    • Health Canada Updates
    • Importation of NHPs
    • Industry Insight
    • Innovation
    • Medical Device
    • Medical Devices
    • MoCRA
    • MoCRA
    • Natural Health Products
    • New Mexico
    • Oregon Toxic-Free Cosmetics Act
    • OTC Drugs
    • OTC Sunscreen Monograph Update
    • Our View
    • Prop 65
    • Research/Science/Technology
    • Toxic-Free Cosmetics Act
    • U.S. Regulatory
    • U.S. State Updates
    • Uncategorized
    Copyright © 2025 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY